Aprogen Biologics
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
Aprogen Biologics makes prescription medicines, both conventional small-molecule drugs and biologic medicines (complex drugs derived from living cells), and distributes them to wholesalers, hospitals, clinics, and pharmacies across Korea.
Listed on KOSPI, Korea's main stock exchange, it operates through subsidiaries that handle distribution and, more recently, semiconductor equipment parts. Its pharmaceutical business is divided into a generics segment, producing drugs for cardiovascular, central-nervous-system, digestive, and metabolic conditions, and a biologics segment focused on antibody medicines.
Summary is AI-generated and may contain errors · figures from DART filings
Its biologics manufacturing facility is located in Osong, Chungbuk, and uses a continuous perfusion-culture process to produce antibody drug substances at large scale.
Aprogen Biologics in five facts
What does Aprogen Biologics do?
Aprogen Biologics makes prescription medicines, both conventional small-molecule drugs and biologic medicines (complex drugs derived from living cells), and distributes them to wholesalers, hospitals, clinics, and pharmacies across Korea.
Where is Aprogen Biologics listed and in which sector?
Aprogen Biologics (Korean name: 에이프로젠바이오로직스) trades under KRX code 003060 on KOSPI, the main board of the Korea Exchange. It is classified in the Health Care sector, Pharmaceuticals.
How large is Aprogen Biologics?
Its market capitalisation was US$31.5M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were Aprogen Biologics's latest annual revenue and operating profit?
For fiscal year 2025, Aprogen Biologics reported revenue of US$55.3M, an operating loss of US$45.6M and a net loss of US$127M, per its annual report on DART (data retrieved from DART on 2026-09-06). Revenue was up 8.7% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-09-06
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- DisclosureOct 8
- Report on large shareholdings (5% rule) (standard)Oct 8
- DisclosureOct 6
- Change in shares held by the largest shareholderOct 2
- Report on securities held by executives/major shareholdersOct 2
- Report on large shareholdings (5% rule) (standard)Oct 2
- Results of rights offering or equity-linked bond issuance (voluntary)Capital raise · Sep 23
- DisclosureSep 23
- [Amended] Material event report (rights offering)
Aprogen Biologics updated the terms of convertible bonds to raise US$14.7M, about 78.5% of its market value.
Capital raise · Sep 23 · 3 versions - Report on large shareholdings (5% rule) (standard)Sep 11
- Report on securities held by executives/major shareholdersSep 2
- Report on large shareholdings (5% rule) (standard)Sep 2
- Report on large shareholdings (5% rule) (abbreviated)Sep 2
- Results of rights offering or equity-linked bond issuance (voluntary)
Aprogen Biologics, Inc. completed a third-party-allotment rights offering of 1,087,548 common shares for US$1.37M, fully paid in on July 27, 2026, following a board resolution on July 14, 2026.
Capital raise · Jul 27 - Material event report (rights offering)
Aprogen Biologics disclosed convertible bonds to raise US$1.34M, about 7.8% of its market value.
Capital raise · Jul 14 - Results of rights offering or equity-linked bond issuance (voluntary)Capital raise · Jul 1
- [Amended] Material event report (convertible bonds)
Aprogen Biologics updated the terms of convertible bonds to raise US$32.9M, about 199.4% of its market value.
Capital raise · Jun 29 · 5 versions - Results of rights offering or equity-linked bond issuance (voluntary)Capital raise · May 29
- Material event report (convertible bonds)
Aprogen Biologics disclosed convertible bonds to raise US$6.65M, about 39.2% of its market value.
Capital raise · May 21 - Results of rights offering or equity-linked bond issuance (voluntary)Capital raise · Apr 27
- Material event report (rights offering)
Aprogen Biologics disclosed a private placement (third-party allotment) to raise US$1.35M, about 7.8% of its market value.
Capital raise · Apr 13 - Change of 30% or more in revenue or profit/loss structure (15% for large companies)
Aprogen Biologics reported consolidated results for FY2025: revenue of US$51.1M (+8.7% year on year), an operating loss of US$42.2M and a net loss of US$114M.
Earnings · Feb 27